JOINN (06127) Plans to Invest Up to RMB 10 Million in Establishing Biomedical Fund

Stock News
2025/08/26

JOINN (06127) announced that to leverage the advantages of professional investment institutions in resources, professional judgment, and investment management, the company or its designated subsidiary intends to sign a Partnership Agreement with Shenzhen Yifeng Investment Management Enterprise (Limited Partnership) ("Yifeng Capital"), Shenzhen Yifeng Mingyuan Technology Co., Ltd. ("Yifeng Mingyuan"), and other relevant parties to establish the Shenzhen Yifeng Guangming Science City Seed Fund (Limited Partnership) (the "Fund" or "Partnership Enterprise").

The partnership enterprise will focus on developing strategic emerging industries, future industries, and other key industries supported and encouraged by the Shenzhen municipal government, with particular emphasis on investments in biomedicine and high-end medical device sectors. The company or its designated subsidiary will serve as a limited partner with a capital commitment not exceeding RMB 10 million.

On August 26, 2025, the company held the 15th meeting of the fourth Board of Directors, which reviewed and approved the "Proposal on the Company's Cooperation with Professional Investment Institutions to Participate in Investment and Establishment of Fund," agreeing to invest no more than RMB 10 million to participate in establishing the fund.

According to the announcement, this investment fund initiative aligns with the company's long-term development strategy. By leveraging the resources, professional experience, and investment management advantages of various partners, it will help the company broaden industrial investment channels and provide momentum and guarantee for achieving sustainable high-quality development. Additionally, by utilizing the fund manager's management experience and risk control system, the company can effectively control investment risks and ensure investment project quality, which serves the interests of both the company and its shareholders.

This investment will not have a significant adverse impact on the company's production operations and performance, does not involve management changes, personnel arrangements, land leasing, or other situations, and will not create competition within the same industry.

免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。

熱議股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10